RNA Therapeutics Market

The global RNA Therapeutics Market is valued at USD 13.3 Billion in 2023 and is projected to reach a value of USD 21.43 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 5.45% between 2024 and 2032.

Key highlights of RNA Therapeutics Market

• In 2023, North America exhibited its market prowess, achieving the highest revenue share of over 34.4%
• The Europe region is poised for remarkable growth, displaying a significant market share in 2023
• Vaccine’s segment dominates the market with largest market share in 2023
• The mRNA Therapeutics segment will continue to assert its dominance by type, capturing the largest market share in 2023
• Infectious Diseases accounts for significant market share in 2023
• Hospitals and Clinics accounts for largest market share of 58.5% in 2023
• The investigation of RNA therapies for the treatment of a variety of illnesses, including uncommon genetic diseases and specific cancers, has also been accelerated by a growing understanding of RNA's function in genetic control and disease pathways

RNA Therapeutics Market: Regional Overview

North America Dominated Sales with a 34.4% share in 2023. Various factors contribute to the region's significance, including a strong research and development infrastructure and a regulatory framework conducive to innovation and commercialization. For instance, The Food and Drug Administration's Office of Orphan Products Development (OOPD) made a funding announcement in 2022 regarding the availability of funds to support research into rare diseases and conditions. Moreover, the notable market share in RNA therapies sales in North America can be linked to increasing investments in cutting-edge technology, a well-established healthcare system, and a high incidence of chronic diseases. The market in North America will be driven by the availability of substantial financing for research, the growth of federal initiatives aimed at RNA-based therapies, and the rising number of clinical studies.

U.S. RNA Therapeutics Market Overview

The U.S. RNA Therapeutics market, valued at USD 4.2 Billion in 2023 to USD 6.03 Billion in 2032 is anticipated to grow at a CAGR of 4.1% from 2024 to 2032. The U.S. RNA Therapeutics market is witnessing significant growth driven by advancements in biotechnology, particularly in the field of RNA-based therapies. For instance, in 2020, Globocan reports that 10 million cancer-related fatalities and 19.3 million new cases of cancer were reported globally. Due to the rise in research and development endeavors, coupled with significant investments from pharmaceutical firms and government initiatives, the market is experiencing rapid expansion. Moreover, the approval of several RNA-based drugs by regulatory authorities underscores the growing acceptance and adoption of these therapies in clinical settings.

The global RNA Therapeutics market can be categorized as Product, Туре, Indication, End User and Region.

RNA Therapeutics Market: Product Overview

In 2023, the Vaccines segment dominated the market with significant market share. The {Keyword}} market, segmented by product, includes Vaccines and drugs. The crucial part that vaccines based on RNA play in the field of therapeutic applications as a whole. The efficacy of mRNA vaccines in preventing infectious diseases most notably, as shown during the global response to the COVID-19 pandemic—has increased funding and awareness in this field. For instance, the first patient in the Phase 2 trial of the monovalent and bivalent modified mRNA COVID-19 vaccine candidates, created in association with GSK, received a dose, according to a press release from CureVac in August 2023. Because of their effectiveness, rapid creation, and versatility, RNA vaccines have established themselves as a potentially useful tool for treating a wide range of other health issues in addition to infectious diseases. For instance, Moderna declared in March 2022 that it had started its second phase 1 HIV vaccine trial. This most recent phase 1 trial (HVTN 302) assesses the safety and immunogenicity of their investigational HIV trimer mRNA vaccine (mRNA-1574) across many centers in an open-label, randomized fashion. The vaccines segment's prominence and long-lasting influence on the larger RNA therapeutics market can be seen by the frequency of continuing research and development projects within it.

RNA Therapeutics Market: Туре Overview

In 2023, the mRNA Therapeutics segment accounted for largest market share. Type segment is divided into mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, Other Therapeutics. This market has risen to prominence due to the use of mRNA technology in vaccine production, as demonstrated by the worldwide response to the COVID-19 pandemic. The market position of mRNA Therapeutics has been strengthened further by the explosion of research and development projects across a wide range of therapeutic disciplines, driven by the adaptability of mRNA in encoding proteins and eliciting desirable cellular responses.

RNA Therapeutics Market: Indication Overview

In 2023, the Infectious Diseases segment accounted for significant market share. Indication segment is divided into Infectious Diseases, Rare Genetic, Diseases/Hereditary Diseases, Other Indications. This emphasizes the significance RNA-based therapies are in treating infectious diseases, particularly in view of the international community's reaction to the COVID-19 pandemic. The market for RNA therapeutics has seen a surge in the therapeutic indications of this category due to the swift and successful development of mRNA vaccines against infectious organisms. Significant research and development efforts have been made in this field as a result of the continued emphasis on eradicating infectious diseases and the progress made in RNA technologies. This has reinforced the Infectious Diseases segment's role as a major force behind growth and innovation in the larger RNA therapeutics market.

RNA Therapeutics Market: End User Overview

In 2023, the Hospitals and Clinics segment accounted for 58.5% of market share. End Use segment is divided into Hospitals and Clinics, Research Settings. The administration and implementation of RNA-based medicines heavily depends on healthcare institutions. Hospitals and clinics are essential centers for the diagnosis, treatment, and management of a wide range of illnesses. Their involvement in the uptake of RNA therapies is indicative of the increasing incorporation of cutting-edge therapeutic modalities into well-established healthcare systems. The demand for these environments highlights how crucial it is to provide RNA therapeutics in a regulated and supervised setting, which has a substantial impact on the market environment as a whole and the growing adoption of these cutting-edge treatments in clinical practice.

Key Trends

• Increasing exploration of RNA therapeutics for the treatment of rare diseases, with a focus on developing targeted therapies addressing specific genetic mutations.
• Continued emphasis on overcoming delivery challenges associated with RNA therapeutics through the development of innovative delivery technologies, enhancing the efficiency and specificity of RNA delivery to target cells.
• The exploration of personalized medicine approaches using RNA therapeutics, tailoring treatments based on an individual's genetic profile for enhanced efficacy and reduced side effects.
• The emergence and development of RNA editing technologies, such as CRISPR-based systems, offering new possibilities for precise modifications of RNA molecules to correct genetic defects.

Premium Insights

The market for RNA therapies is driven by multiple factors that promote its expansion and advancement. The astounding success of messenger RNA (mRNA) technology is a major motivator. This is best demonstrated by the quick creation and broad adoption of mRNA-based vaccinations against infectious diseases. For instance, A Phase 1 clinical trial has been initiated by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, to assess three experimental HIV vaccines that rely on the messenger RNA (mRNA) platform—a technology that has been employed in multiple COVID-19 vaccines that have been authorized. The study, also known as HVTN 302, is being carried out by the HIV Vaccine Trials Network (HVTN), which is supported by NIAID and is situated at the Fred Hutchinson Cancer Research Center in Seattle. Beyond vaccines, RNA's versatility in encoding proteins and inducing certain cellular responses has expanded its applicability, spurring research and development activities in a variety of therapeutic domains. Supportive regulatory frameworks and a condition that encourages innovation have helped to drive market improvements even more.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Advances in molecular biology have deepened our understanding of RNA's pivotal role in genetic regulation and disease pathways, propelling the exploration of RNA therapeutics for diverse disorders

This newfound understanding has accelerated research into developing targeted therapies for rare genetic diseases and specific types of cancers. RNA's ability to modulate gene expression offers a unique approach to intervene in disease mechanisms at the molecular level, paving the way for innovative treatments that address the underlying causes of various medical conditions. This shift in focus from symptomatic treatment to precision medicine holds immense promise for advancing therapeutic options and improving patient outcomes.

As research continues to uncover the full potential of RNA, particularly in targeting specific genetic and molecular mechanisms, unprecedented opportunities arise for developing therapies across a broad spectrum of diseases

The versatility of RNA-based approaches allows for precise interventions in disease pathways, offering potential treatments for neurodegenerative disorders, genetic mutations, and a range of cancers. For instance, Eli Lilly and Company invested USD 700.0 million in February 2022 to construct a facility at the Port of Boston to support its research and development endeavors focused on RNA. This expanding scope of RNA therapeutics underscores its transformative impact on medicine, with the potential to address previously challenging-to-treat conditions and significantly improve the therapeutic landscape.

Increasing emphasis on precision medicine and personalized therapies aligns with the unique capabilities of RNA therapeutics

The ability to tailor treatments based on individual genetic profiles positions RNA therapies as key players in the evolving landscape of personalized medicine. This focus has created opportunities for collaboration, strategic partnerships, and targeted investments within the RNA therapeutics market. Companies and research institutions are seizing these opportunities to advance the development of customized therapeutic solutions, contributing to a paradigm shift in how diseases are understood and treated at the molecular level. For instance, a four-year exclusive research agreement centered on in vivo base editing programs targeting three targets for uncommon genetic illnesses of the liver, muscle, and central nervous system was established in January 2022 by Pfizer Inc. and Beam Therapeutics Inc. By combining Beam therapeutics’ in vivo delivery technologies—which deliver base editors to target organs via messenger RNA (mRNA) and lipid nanoparticles (LNPs)—with Pfizer's experience in the development of medications and vaccines, this partnership has the potential to create innovative therapeutics for patients with rare diseases. The convergence of precision medicine and RNA therapeutics holds promise for more effective and tailored approaches to healthcare.

Competitive Landscape

The RNA Therapeutics market is highly competitive, marked by the presence of key players engaging in strategic initiatives to gain a significant market share. Companies such as Moderna, Pfizer, CureVac, and Alnylam Pharmaceuticals are at the forefront, leveraging their expertise in mRNA and RNAi technologies. Additionally, advancements in RNA delivery technologies and increasing investments in clinical trials contribute to the competitive intensity. The market is predicted to become even more competitive as the need for novel RNA-based treatments increases. To stay ahead in this quickly changing industry, businesses will likely concentrate on obtaining regulatory approvals and innovations in technology.

The key players in the global RNA Therapeutics market include - Moderna, Inc., BioNTech SE, CureVac N.V., Arcturus Therapeutics, Translate Bio, Inc., GSK plc., Argos Therapeutics Inc., Sangamo Therapeutics, Inc., Pfizer Inc., AstraZeneca plc., CRISPR Therapeutics AG among others.

Recent Market Developments

• In February 2023, Health Canada authorized Moderna, Inc. for sale as mRNA-1273.214 (SpikevaxBivalent Original/Omicron), the COVID-19 booster vaccine. The purpose of this vaccination is to immunize children and adolescents aged 6 to 17 against COVID-19.
• In June 2023, the investigational mRNA vaccine candidate mRNA-1345 from Moderna was awarded Breakthrough Therapy Designation by the US FDA. The purpose of this vaccination is to protect individuals 60 years of age and above from RSV-associated lower respiratory tract illness (RSV-LRTD).
• In September 2022, The European Commission authorized Alnylam Pharmaceuticals, Inc. to launch AMVUTTRA, an RNAi treatment. This therapy was created for adult patients suffering from hereditary transthyretin-mediated polyneuropathy (hATTR) stage 1 or stage 2.